semaglutide patent expiry europe Novo Nordisk Settles Ozempic Case A Snapshot of the Semaglutide

While Semaglutide GLP-1 is broadly applicable for many patients struggling with significant weight-related concerns, it is not suitable for everyone

Notably, the SUSTAIN-6 trial demonstrated cardiovascular benefits, showing a significant reduction in major adverse cardiovascular events among patients treated with semaglutide compared to those receiving placebo

Nausea, bloating, constipation, and delayed gastric emptying are common side effects and many of these symptoms overlap with endometriosis-related bowel and pelvic discomfort

In comparison, vitamin B6 has a prominent role in hormone regulation, neurotransmitter synthesis, and protein synthesis

It is written from the perspective of board-certified Emergency Medicine physicians who manage weight-loss medications inside a real, longitudinal practice, not a one-visit telehealth funnel